Nanotechnology approaches for global infectious diseases

• Published in: Nature nanotechnology Vol. 16; no. 4; pp. 369 - 384
• Main Authors: Kirtane, Ameya R., Verma, Malvika, Karandikar, Paramesh, Furin, Jennifer, Langer, Robert, Traverso, Giovanni
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.04.2021; Nature Publishing Group
• Subjects: 631/61/350; 631/61/54; Bioavailability; Chemistry and Materials Science; HIV; Human immunodeficiency virus; Infectious diseases; Malaria; Materials Science; Microorganisms; Morbidity; Mortality; Nanotechnology; Nanotechnology and Microengineering; Public health; Review Article; Sanctuaries; Tuberculosis; Vector-borne diseases
• ISSN: 1748-3387; 1748-3395
• DOI: 10.1038/s41565-021-00866-8

Infectious diseases are a major driver of morbidity and mortality globally. Treatment of malaria, tuberculosis and human immunodeficiency virus infection are particularly challenging, as indicated by the ongoing transmission and high mortality associated with these diseases. The formulation of new and existing drugs in nano-sized carriers promises to overcome several challenges associated with the treatment of these diseases, including low on-target bioavailability, sub-therapeutic drug accumulation in microbial sanctuaries and reservoirs, and low patient adherence due to drug-related toxicities and extended therapeutic regimens. Further, nanocarriers can be used for formulating vaccines, which represent a major weapon in our fight against infectious diseases. Here we review the current burden of infectious diseases with a focus on major drivers of morbidity and mortality. We then highlight how nanotechnology could aid in improving existing treatment modalities. We summarize our progress so far and outline potential future directions to maximize the impact of nanotechnology on the global population. This Review outlines the potential applications of nanotechnology-based treatments for infectious diseases, with a specific focus on the progress and challenges in developing nanomedicines against HIV, tuberculosis and malaria.